Revolution (RVMD) PT Raised to $144 at Wells Fargo

Wells Fargo analyst Eva Fortea Verdejo raised the price target on Revolution (NASDAQ: RVMD) to $144.00 (from $100.00) while maintaining a Overweight rating.

The analyst comments "The co is on track for their first pivotal readout in 1H26 and we are confident on daraxon's potential in 2L PDAC. Beyond RASolute 302, we are watching out for updated 1L data for daraxon and PDAC zoldon data. RASolute 302 on track for 1H26. Recall, based on our stats the study is powered to detect ~6mo (Δ3mo) mPFS and ~10.5mo (Δ4.5mo) mOS benefit in G12X pts (see our init here), which we think daraxon is well positioned to deliver. We view this as a key catalyst for RVMD. While the 2L oppty is mostly baked into the stock at these levels, we believe a meaningful benefit in 2L could read through to the 1L study. Mgmt plans to use the CNPV for the 2L oppty and we expect a launch in 2027."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Full Circle Lithium closes $5.14M private placement